SECsense Logo

Co-Diagnostics, Inc. SEC Form 8-K: Key Insights & Updates for Investors

$CODX
Form 8-K
Filed on: 2025-01-10
Source
Co-Diagnostics, Inc. SEC Form 8-K: Key Insights & Updates for Investors

Based on the provided section of the financial report, here are the key pieces of information and insights:

  1. Filing Type: The document is an SEC Form 8-K, indicating it is a current report used to announce major events that shareholders should know about. This is particularly relevant for investors looking to understand significant changes or updates within the company.
  2. Company Information:
  • Name: Co-Diagnostics, Inc.
  • CIK: 0001692415
  • Address: 2401 S. Foothill Drive Suite D, Salt Lake City, UT 84109
  • Phone Number: (801) 438-1036
  • Stock Ticker: CODX (listed on NASDAQ)
  • Par Value of Common Stock: $0.001 per share
  1. Reporting Date: The report is dated January 10, 2025, which suggests that the information is current as of that date.
  2. Contextual Information:
  • The context ID is "AsOf2025-01-10," which refers to the specific date for the relevant financial data.
  • The report provides information in USD (United States Dollars) and shares, indicating that it includes financial metrics relevant to both currency and equity.
  1. Tax Identification: The company has an Employer Identification Number (EIN) of 46-2609363.
  2. Units of Measure:
  • Financial measures are provided in USD and shares, suggesting that the report will detail financial performance in monetary terms and possibly in terms of share quantities.

Insights:

  • As an 8-K filing, this report may contain crucial updates regarding corporate actions, financial performance, or other significant events affecting the company. Investors should look for additional context in the complete filing to assess any implications for Co-Diagnostics, Inc.
  • The company's small par value of $0.001 per share could indicate a higher number of outstanding shares, which might be relevant for understanding the company's capital structure and market capitalization.
  • The report's date being in the future (2025) suggests it might be part of a planned schedule or a pre-announcement of forthcoming performance metrics or corporate changes.

Overall, stakeholders should monitor the complete report for details that could impact investment decisions or the company’s future performance.